Drugs / MOMA-313
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06545942 | Aug 2024 → May 2027 expected | breast cancer, metastatic neoplasm, ovarian cancer, pancreatic neoplasm +1 | MOMA Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOMA-313 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06545942 ↗ |
| Route | Oral | “MOMA-313 administered orally” NCT06545942 ↗ |